116 results
Page 5 of 6
8-K
EX-99.2
m37olwug
10 Oct 19
Entry into a Material Definitive Agreement
9:39pm
8-K
EX-2.1
8qy2w9wnn0m3
10 Oct 19
Entry into a Material Definitive Agreement
9:39pm
8-K
EX-99.1
app03e
8 Aug 19
Undertaking strategic review of commercial and R&D assets
4:15pm
8-K
EX-99.1
3b3wytlv9s1
5 Jun 19
Regulation FD Disclosure
7:01am
8-K
EX-99.1
70cmw
8 May 19
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
4:15pm
8-K
EX-99.1
gaq2wlo
4 Apr 19
Regulation FD Disclosure
7:06am
8-K
EX-99.1
3schsrdqrzot1nk04
18 Mar 19
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
7:15am
8-K/A
EX-99.2
259obs
18 Jan 19
Financial Statements and Exhibits
4:34pm
8-K/A
EX-99.3
5dm 0rbr3h
18 Jan 19
Financial Statements and Exhibits
4:34pm
8-K/A
EX-23.2
xrrxhwzo7k3i1g9dlr
18 Jan 19
Financial Statements and Exhibits
4:34pm
8-K
EX-99.1
7x8zvn
6 Nov 18
Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
4:15pm
424B5
urfp217nj zpbk2ncd
18 Oct 18
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.3
0d6ai
18 Oct 18
Aclaris Announces Proposed Public Offering of Common Stock
4:01pm
424B5
lu37nn9vkj57n
17 Oct 18
Prospectus supplement for primary offering
4:04pm